🇺🇸 FDA
Patent

US 6825323

Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same

expired A61KA61K38/36

Quick answer

US patent 6825323 (Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same) held by The United States of America as represented by the Secretary of the Army expires Mon Nov 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Nov 30 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K38/36